Literature DB >> 2363735

Importance of the IgG isotype, not the state of glycosylation, in determining human rheumatoid factor binding.

M M Newkirk1, A Lemmo, J Rauch.   

Abstract

We investigated the influence of carbohydrate on the binding of human rheumatoid factors (RF) to the Fc fragment of IgG. The monoclonal RF studied were derived from the serum of patients with mixed cryoglobulinemia or from hybridomas generated from patients with rheumatoid arthritis (RA) and systemic lupus erythematosus. Polyclonal RF were derived from patients with RA. The carbohydrate located on the Fc fragment, regardless of whether it contained different amounts of mannose or reduced amounts of galactose, or was removed, did not affect the binding of the RF. In contrast, the isotype of the Fc was found to be critical. Two groups of hybridoma RF could be delineated. One group bound preferentially to IgG1 and/or IgG2, and a second group (primarily from patients with RA) bound preferentially to IgG3 and/or IgG4. Our results indicate that the isotype of the Fc fragment, and not the extent of galactosylation, influences the binding of the RF.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2363735     DOI: 10.1002/art.1780330606

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  3 in total

1.  Monospecific but not polyreactive human hybridoma rheumatoid factors exhibit preferential binding specificities for IgG3 and IgG4.

Authors:  M M Newkirk; J Rauch
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

2.  Changes in normal glycosylation mechanisms in autoimmune rheumatic disease.

Authors:  J S Axford; N Sumar; A Alavi; D A Isenberg; A Young; K B Bodman; I M Roitt
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

3.  Rheumatoid factor avidity in patients with rheumatoid arthritis: identification of pathogenic RFs which correlate with disease parameters and with the gal(0) glycoform of IgG.

Authors:  M M Newkirk; M J Fournier; J Shiroky
Journal:  J Clin Immunol       Date:  1995-09       Impact factor: 8.317

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.